Punit Dhillon was named President and Chief Executive Officer of Skye Bioscience, Inc., effective September 8, 2026. As of November 6, 2026, Skye Bioscience, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 3, 2026 to September 11, 2026, naming 2 appointments and 1 departure (Form 8-K, September 11, 2026).
Skye Bioscience, Inc. named a new President and Chief Executive Officer on Sep 11. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Skye Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Skye Bioscience, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-03 to 2026-09-11. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Skye Bioscience, Inc. files it.
Also on the record for Skye Bioscience, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 14, 2026 | Stake report, Schedule 13G, by TANG CAPITAL MANAGEMENT, LLC | 6% of the class | 5%+ stakes | Source |
| September 24, 2026 | Stake report, Schedule 13D/A, by 5AM Partners VII, LLC | 26.1% of the class | 5%+ stakes | Source |
| August 18, 2026 | Stake report, Schedule 13D/A, by 5AM Partners VII, LLC | 30.2% of the class | 5%+ stakes | Source |
| December 16, 2025 | Stake report, Schedule 13D/A, by 5AM Partners VII, LLC | 34% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Schonfeld Strategic Advisors LLC | 3.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Skye Bioscience, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Skye Bioscience, Inc. and the records around it.
Skye Bioscience, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- 5AM Partners VII, LLC also filed stake reports on 1 other company: Surrozen, Inc. (Aug 2026)
- Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies: Inhibrx Biosciences, Inc. (Aug 2026), Cardinal Infrastructure Group Inc. (May 2026), Jiuzi Holdings, Inc. (Feb 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026), Capricor Therapeutics, Inc. (Aug 2026)
Watch Skye Bioscience, Inc.
Get an email when Skye Bioscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Skye Bioscience, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Skye Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Skye Bioscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-11 | Out | Chief Financial Officer | 8-K, 2026-09-11 | ||
| 2026-09-11 | In | President and Chief Executive Officer | 2026-09-08 | 8-K, 2026-09-11 | |
| 2026-04-03 | In | Chief Financial Officer | 8-K, 2026-04-03 |
Who leads Skye Bioscience, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: John P. Sharp, departure reported (filed 2026-09-11). No successor is named in these filings.
- President and Chief Executive Officer: Punit Dhillon, appointed, effective 2026-09-08 (filed 2026-09-11).
New leaders reset buying decisions — get the Full Report on Skye Bioscience, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Skye Bioscience, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Skye Bioscience, Inc.Every change, in the filing's words
Departing: John P. Sharp, Chief Financial Officer
On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.
Appointed: Punit Dhillon, President and Chief Executive Officer, effective 2026-09-08
Appointment of Principal Financial and Accounting Officer In connection with Mr. Sharp's departure, on September 9, 2026, the Board of Directors of the Company appointed Punit Dhillon, the Company's President and Chief Executive Officer, as the Company's principal financial and accounting officer, effective as of September 8, 2026.
- Mr. Sharp's departure is not the result of any disagreement with the Company's independent auditors or the Company on any matter relating to the Company's financial statements, internal control over financial reporting, operations, policies or practices.
- Mr. Dhillon will continue in his roles as Director, President and Chief Executive Officer of the Company.
- The compensatory and other material terms of Mr. Dhillon's employment with the Company will remain unchanged in connection with the foregoing.
Appointed: John P. Sharp, Chief Financial Officer
The Repriced Options include underwater options held by Punit Dhillon, the Company's President and Chief Executive Officer and the principal executive officer, financial and accounting officer of the Company, and Tuan Diep, the Company's Chief Operating Officer, as set forth below: Name and Position Total Repriced Options Original Exercise Price of Repriced Options Punit Dhillon President and Chief Executive Officer 1,103,959 $2.89 to $14.56 Tuan Diep Chief Operating Officer 396,295 $2.89 to $14.56 Appointment of Chief Financial Officer On March 31, 2026, the Board appointed John P. Sharp as t
- Pursuant to the Option Repricing, the exercise price of each Repriced Option was reduced to $0.6150 per share, the closing price per share of the Company's common stock on the Repricing Date.
- No additional changes were made to the Repriced Options other than a reduction in the applicable exercise price.
- The Board approved the Option Repricing after careful consideration of various alternatives and a review of other applicable factors.
- The Board believes the Option Repricing is in the best interests of the Company and its stockholders, as it will provide added incentives to retain and motivate the Eligible Participants without incurring the dilution resulting from additional equity grants under the Plans or additional cash expenditures resulting from additional cash compensation.
- The total number of shares of common stock of the Company underling all Repriced Options is 2,420,978 shares.
- The Repriced Options previously had per share exercise prices ranging from $1.055 to $14.56.
- Mr. Sharp will also serve as the Company's principal financial and accounting officer, effective March 31, 2026.
- Mr. Sharp, age 61, is a seasoned finance executive with more than 30 years of experience in financial and business planning and currently serves as a Senior Director at Lohman & Associates ("L&A").
- Since April 2007, he has served as chief financial officer for several biopharmaceutical companies.
Tools for this story
Each opens in a new tab, filled in for Skye Bioscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.